NILOTINIB INDUCES RAPID AND DURABLE RESPONSES WITH 24-MONTH MINIMUM FOLLOW-UP IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA IN BLAST CRISIS (CML-BC)

被引：0
|
作者：
Giles, F. [1 ]
Kantarjian, H. [2 ]
le Coutre, P. [3 ]
Baccarani, M. [4 ]
Blakesley, R. [5 ]
Gallagher, N. [6 ]
Gillis, K. [5 ]
Larson, R. [7 ]
Ottmann, O. [8 ]
机构：
[1] CTRC, UT Hlth Sci Ctr, Inst Drug Dev, San Antonio, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Klinikum Berlin, Berlin, Germany
[4] Univ Bologna, Bologna, Italy
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] Novartis Pharma AG, Basel, Switzerland
[7] Univ Chicago, Chicago, IL 60637 USA
[8] Goethe Univ Frankfurt, Frankfurt, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1138
引用
收藏
页码：469 / 469
页数：1
相关论文
共 50 条
  • [1] Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib
    Giles, F. J.
    Kantarjian, H.
    le Coutre, P. D.
    Baccarani, M.
    Blakesley, R. E.
    Gallagher, N. J.
    Gillis, K.
    Larson, R. A.
    Ottmann, O. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
    Giles, F. J.
    Larson, R. A.
    Kantarjian, H. M.
    le Coutre, P.
    Palandri, F.
    Haque, A.
    Gallagher, N.
    Ottmann, O. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
    Cortes, Jorge
    Rousselot, Philippe
    Kim, Dong-Wook
    Ritchie, Ellen
    Hamerschlak, Nelson
    Coutre, Steven
    Hochhaus, Andreas
    Guilhot, Francois
    Saglio, Giuseppe
    Apperley, Jane
    Ottmann, Oliver
    Shah, Neil
    Erben, Philipp
    Branford, Susan
    Agarwal, Prasheen
    Gollerkeri, Ashwin
    Baccarani, Michele
    BLOOD, 2007, 109 (08) : 3207 - 3213
  • [4] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
    Giles, Francis J.
    le Coutre, Phillip
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 311A - 312A
  • [5] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    Giles, F. J.
    le Coutre, P. D.
    Pinilla-Ibarz, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Hochhaus, A.
    Radich, J. P.
    Saglio, G.
    Hughes, T. P.
    Martinelli, G.
    Kim, D-W
    Novick, S.
    Gillis, K.
    Fan, X.
    Cortes, J.
    Baccarani, M.
    Kantarjian, H. M.
    LEUKEMIA, 2013, 27 (01) : 107 - 112
  • [6] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    F J Giles
    P D le Coutre
    J Pinilla-Ibarz
    R A Larson
    N Gattermann
    O G Ottmann
    A Hochhaus
    J P Radich
    G Saglio
    T P Hughes
    G Martinelli
    D-W Kim
    S Novick
    K Gillis
    X Fan
    J Cortes
    M Baccarani
    H M Kantarjian
    Leukemia, 2013, 27 : 107 - 112
  • [7] Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)
    Giles, Francis J.
    Yin, Ophelia
    Chia, Yen Lin
    le Coutre, Philipp D.
    Woodman, Richard C.
    Ottmann, Oliver G.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 390 - 390
  • [8] DASATINIB EFFICACY IN PATIENTS WITH IMATINIB-RESISTANT/-INTOLERANT CHRONIC MYELOID LEUKEMIA IN BLAST PHASE: 24-MONTH DATA FROM THE START PROGRAM
    Saglio, G.
    Dombret, H.
    Rea, D.
    Corm, S.
    Cortes, J.
    Kim, D. W.
    Garzon, F. T.
    Paliwal, P.
    Baccarani, M.
    Martinelli, G.
    Gambacorti-Passerini, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 349 - 349
  • [9] Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
    Giles, Francis J.
    Larson, Richard A.
    Kantarjian, Hagop M.
    le Coutre, Philipp
    Baccarani, Michele
    Haque, Ariful
    Gallagher, Neil
    Ottmann, Oliver G.
    BLOOD, 2007, 110 (11) : 310A - 310A
  • [10] Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis J.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Branford, Susan
    Mueller, Martin C.
    Shou, Yaping
    Novick, Steven
    Fan, Xiaolin
    Cortes, Jorge E.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1610 - 1610
12345